Intervacc announces submission of the Marketing Authorization Application for Strangvac to the European Medicines Agency
Stockholm February 26, 2020 - Intervacc AB (publ) announces that the Company’s Marketing Authorization Application (MAA) for review of Strangvac has been submitted today to the European Medicines Agency (EMA). Intervacc is seeking approval for Strangvac as a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally.
“The MAA filing represents a significant milestone for Intervacc. We are now submitting a regulatory application for marketing authorization for our first in-house developed vaccine and take a major step toward preventing outbreaks